John Mac
Senior Member (Voting Rights)
From news email
Open Medicine Foundation
As part of our annual Triple Giving November campaign, we are pleased to highlight an additional 2022 OMF supported research initiative. This study is in collaboration between Christopher W. Armstrong, PhD, Director of the Melbourne ME/CFS Collaboration, and Jonas Bergquist, MD, PhD, Director of the Uppsala Collaborative Research Center.
High Frequency Blood Sampling
Principal Investigators
Christopher W. Armstrong, PhD
Jonas Bergquist, MD, PhD
ME/CFS is a complex disease that varies from one patient to another and even from hour to hour. It is a disease defined by its symptoms and yet these symptoms vary both between patients and within patients over time. While research in recent decades has identified many areas of dysfunction in the bodies of ME/CFS patients, we still lack comprehensive knowledge of how all the parts fit together. All people experience subtle biological changes during food digestion, stress, and both physical and mental exertion, however, ME/CFS patients can have physical changes in symptom expression in response to these. Few studies have explored how symptoms change in patients, from day to day or even hour to hour.
This study plans to use high frequency blood testing—multiple tests over a 6–8-hour period—to evaluate what changes in ME/CFS patients over the course of a day.
The study will also examine changes based on cognitive, social, and physical tasks and food consumption. Based on the latest technology in multiple fields, a wide range of test methods will be used to characterize and compare the biology of ME/CFS patients, healthy controls, and athletes over a day's time. Past research points to dysfunction in how the body creates energy in ME/CFS, so those theories will be explored.
The overall goal is to better understand the biological mechanisms that underlie changing symptoms in ME/CFS patients that occur in response to different experiences. This information will allow researchers to examine differences and to potentially identify biomarkers and diagnostic tests, as well as evaluate new treatments.
Open Medicine Foundation
As part of our annual Triple Giving November campaign, we are pleased to highlight an additional 2022 OMF supported research initiative. This study is in collaboration between Christopher W. Armstrong, PhD, Director of the Melbourne ME/CFS Collaboration, and Jonas Bergquist, MD, PhD, Director of the Uppsala Collaborative Research Center.
High Frequency Blood Sampling
Principal Investigators
Christopher W. Armstrong, PhD
Jonas Bergquist, MD, PhD
ME/CFS is a complex disease that varies from one patient to another and even from hour to hour. It is a disease defined by its symptoms and yet these symptoms vary both between patients and within patients over time. While research in recent decades has identified many areas of dysfunction in the bodies of ME/CFS patients, we still lack comprehensive knowledge of how all the parts fit together. All people experience subtle biological changes during food digestion, stress, and both physical and mental exertion, however, ME/CFS patients can have physical changes in symptom expression in response to these. Few studies have explored how symptoms change in patients, from day to day or even hour to hour.
This study plans to use high frequency blood testing—multiple tests over a 6–8-hour period—to evaluate what changes in ME/CFS patients over the course of a day.
The study will also examine changes based on cognitive, social, and physical tasks and food consumption. Based on the latest technology in multiple fields, a wide range of test methods will be used to characterize and compare the biology of ME/CFS patients, healthy controls, and athletes over a day's time. Past research points to dysfunction in how the body creates energy in ME/CFS, so those theories will be explored.
The overall goal is to better understand the biological mechanisms that underlie changing symptoms in ME/CFS patients that occur in response to different experiences. This information will allow researchers to examine differences and to potentially identify biomarkers and diagnostic tests, as well as evaluate new treatments.